Troisième partie : Neurotensine et pathologies associées :

III - Références bibliographiques :

Allen A.E., Carney D.N. and Moody T.W. 1988 Neurotensin binds with high affinity to small cell lung cancer cells. Peptides, 9, 57-61.

Allen J.M., Cross A.J., Yeats J.C., Ghatei M.A., McGregor G.P., Close S.P., Pay S., Marriott A.S., Tyers M.B., Crow T.J. and et al. 1986 Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease? Brain, 109, 143-157.

Arnold S.E., Hyman B.T., Van Hoesen G.W. and Damasio A.R. 1991 Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry, 48, 625-632.

Bassett A.S. and Husted J. 1997 Anticipation or ascertainment bias in schizophrenia? Penrose's familial mental illness sample. Am J Hum Genet, 60, 630-637.

Ben-Shlomo Y. 1997 The epidemiology of Parkinson's disease. Baillieres Clin Neurol, 6, 55-68.

Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V. and Greenamyre J.T. 2000 Chronic systemic pesticide exposure reproduces features of Parkinson's disease [In Process Citation]. Nat Neurosci, 3, 1301-1306.

Bilder R.M., Bogerts B., Ashtari M., Wu H., Alvir J.M., Jody D., Reiter G., Bell L. and Lieberman J.A. 1995 Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res, 17, 47-58.

Blaha C.D., Coury A., Fibiger H.C. and Phillips A.G. 1990 Effects of neurotensin on dopamine release and metabolism in the rat striatum and nucleus accumbens: cross-validation using in vivo voltam-metry and microdialysis. Neuroscience, 34, 699-705.

Blaha C.D. and Phillips A.G. 1992 Pharmacological evidence for common mechanisms underlying the effects of neurotensin and neuroleptics on in vivo dopamine efflux in the rat nucleus accumbens. Neuroscience, 49, 867-877.

Bogerts B., Ashtari M., Degreef G., Alvir J.M., Bilder R.M. and Lieberman J.A. 1990 Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res, 35, 1-13.

A.J. Brookes and D. St Clair 1994, Synuclein proteins and Alzheimer's disease, Trends Neurosci, 17, 10, 404-5

Chabry J., Gaudriault G., Vincent J.P. and Mazella J. 1993 Implication of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neurons. J Biol Chem, 268, 17138-17144.

Chinaglia G., Probst A. and Palacios J.M. 1990 Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia. Neuroscience, 39, 351-360.

Dal-Farra C., Sarret P., Navarro V., Botto J.M., Mazella J. and Vincent J.P. 2001 Involvement of the neurotensin receptor subtype ntr3 in the growth effect of neurotensin on cancer cell lines. Int. J. Cancer, 92, pp.

Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., Artiges E., Feline A., Syrota A. and Martinot J.L. 1997 Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res, 23, 167-174.

Davis T.P., Burgess H.S., Crowell S., Moody T.W., Culling-Berglund A. and Liu R.H. 1989 Beta-endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur J Pharmacol, 161, 283-285.

Davis T.P., Crowell S., McInturff B., Louis R. and Gillespie T. 1991 Neurotensin may function as a regulatory peptide in small cell lung cancer. Peptides, 12, 17-23.

Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A. and Mechoulam R. 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.

Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S. and Grasby P.M. 1995 Dopami-nergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature, 378, 180-182.

Ervin G.N., Birkemo L.S., Nemeroff C.B. and Prange, A.J. Jr. 1981 Neurotensin blocks certain ampheta-mine-induced behaviours. Nature, 291, 73-76.

Evers B.M., Izukura M., Townsend C.M.Jr., Uchida T. and Thompson J.C. 1990 Differential effects of gut hormones on pancreatic and intestinal growth during administration of an elemental diet. Ann Surg, 211, 630-636; discussion 636-638.

Evers B.M., Ishizuka J., Chung D.H., Townsend C.M.Jr. and Thompson J.C. 1992a Neurotensin expression and release in human colon cancers. Ann Surg, 216, 423-430; discussion 430-421.

Evers B.M., Izukura M., Chung D.H., Parekh D., Yoshinaga K., Greeley G.H.Jr., Uchida T., Townsend, C.M.Jr. and Thompson J.C. 1992b Neurotensin stimulates growth of colonic mucosa in young and aged rats. Gastroenterology, 103, 86-91.

Evers B.M., Izukura M., Townsend C.M.Jr., Uchida T. and Thompson J.C. 1992c Neurotensin prevents intestinal mucosal hypoplasia in rats fed an elemental diet. Dig Dis Sci, 37, 426-431.

Evers B.M., Rajaraman S., Chung D.H., Townsend C.M.Jr., Wang X., Graves K. and Thompson J.C. 1993 Developmental expression of the neurotensin gene in the rat liver. Ann Surg, 218, 183-188.

Feifel D., Reza T.L. and Robeck S.L. 1997 Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides, 18, 1457-1460.

Feifel D., Reza T.L., Wustrow D.J. and Davis M.D. 1999 Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther, 288, 710-713.

Fernandez A., de Ceballos M.L., Jenner P. and Marsden C.D. 1994 Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience, 61, 73-79.

Fernandez A., Jenner P., Marsden C.D. and De Ceballos M.L. 1995 Characterization of neurotensin-like immunoreactivity in human basal ganglia: increased neurotensin levels in substantia nigra in Parkinson's disease. Peptides, 16, 339-346.

Fernandez A., de Ceballos M.L., Rose S., Jenner P. and Marsden C.D. 1996 Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain, 119, 823-830.

Feurle G.E., Muller B., Ohnheiser G. and Baca I. 1985 Action of neurotensin on size, composition, and growth of pancreas and stomach in the rat. Regul Pept, 13, 53-62.

Feurle G.E., Muller B. and Rix E. 1987 Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats. Gut, 28, 19-23.

Fride E. and Mechoulam R. 1993 Pharmacological activity of the cannabinoid receptor agonist, ananda-mide, a brain constituent. Eur J Pharmacol, 231, 313-314.

Garver D.L., Bissette G., Yao J.K. and Nemeroff C.B. 1991 Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry, 148, 484-488.

Goedert M., Reeve J.G., Emson P.C. and Bleehen N.M. 1984 Neurotensin in human small cell lung carcinoma. Br J Cancer, 50, 179-183.

Hara Y., Shiosaka S., Senba E., Sakanaka M., Inagaki S., Takagi H., Kawai Y., Takatsuki K., Matsuzaki T. and Tohyama M. 1982 Ontogeny of the neurotensin-containing neuron system of the rat: immunohisto-chemical analysis. I. Forebrain and diencephalon. J Comp Neurol, 208, 177-195.

Hermans-Borgmeyer I., Hermey G., Nykjaer A. and Schaller C. 1999 Expression of the 100-kDa neurotensin receptor sortilin during mouse embryonal development. Brain Res Mol Brain Res, 65, 216-219.

Hubble J.P., Cao T., Hassanein R.E., Neuberger J.S. and Koller W.C. 1993 Risk factors for Parkinson's disease. Neurology, 43, 1693-1697.

Iqbal N. and van Praag H.M. 1995 The role of serotonin in schizophrenia. Eur Neuropsycho-pharmacol, 5, 11-23.

Iwase K., Evers B.M., Hellmich M.R., Kim H.J., Higashide S., Gully D. and Townsend C.M., Jr. 1996 Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg Oncol, 5, 245-251.

Iwase K., Evers B.M., Hellmich M.R., Kim H.J., Higashide S., Gully D., Thompson J.C. and Townsend C.M.Jr. 1997 Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer, 79, 1787-1793.

Johnson J.E., Cleary J., Ahsan H., Harkavy Friedman J., Malaspina D., Cloninger C.R., Faraone S.V., Tsuang M.T. and Kaufmann C.A. 1997 Anticipation in schizophrenia: biology or bias? Am J Med Genet, 74, 275-280.

Jolicoeur F.B., De Michele G., Barbeau A. and St-Pierre S. 1983 Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation. Neurosci Biobehav Rev, 7, 385-390.

Jolicoeur F.B., Rivest R., St-Pierre S., Gagne M.A. and Dumais M. 1985 The effects of neurotensin and [D-Tyr11]-NT on the hyperactivity induced by intra-accumbens administration of a potent dopamine receptor agonist. Neuropeptides, 6, 143-156.

Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A. and St-Pierre S. 1991a Neurotensin selectively antagonizes apomorphine-induced stereotyped climbing. Pharmacol Biochem Behav, 38, 463-465.

Jolicoeur F.B., Rivest R., St-Pierre S. and Drumheller A. 1991b Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats. Brain Res, 538, 187-192.

Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A. and St-Pierre S. 1991c Neurotensin selectively antagonizes apomorphine-induced stereotyped climbing. Pharmacol Biochem Behav, 38, 463-465.

Jones A.K., Friston K. and Dolan R. 1991 Positron emission tomography as a research tool in the investigation of psychiatric and psychological disorders. Baillieres Clin Endocrinol Metab, 5, 187-203.

Kablinger A.S. and Freeman A.M. 2000 Prodromal schizophrenia and atypical antipsychotic treatment. J Nerv Ment Dis, 188, 642-652.

Karayiorgou M. and Gogos J.A. 1997a Dissecting the genetic complexity of schizophrenia. Mol Psychiatry, 2, 211-223.

Karayiorgou M. and Gogos J.A. 1997b A turning point in schizophrenia genetics. Neuron, 19, 967-979.

Karlsson P., Smith L., Farde L., Harnryd C., Sedvall G. and Wiesel F.A. 1995 Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl), 121, 309-316.

Kinkead B., Binder E.B. and Nemeroff C.B. 1999 Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry, 46, 340-351.

Kitabgi P., Poustis C., Granier C., Van Rietschoten J., Rivier, J., Morgat, J.L. and Freychet, P. 1980 Neuro-tensin binding to extraneural and neural receptors: comparison with biological activity and structure--activity relationships. Mol Pharmacol, 18, 11-19.

Kitabgi, P., Herve, D., Studler, J.M., Tramu, G., Rostene, W. and Tassin, J.P. 1989 [Neurotensin/ dopamine interactions]. Encephale, 15 Spec No, 91-94.

Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. 1998 Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [see comments]. Nature, 392, 605-608.

Kleinman J.E., Hong J., Iadarola M., Govoni S. and Gillin C.J. 1985 Neuropeptides in human brain--postmortem studies. Prog Neuropsychopharmacol Biol Psychiatry, 9, 91-95.

Kruger R., Kuhn W., Muller T., Woitalla D., Graeber, M., Kosel S., Przuntek H., Epplen J.T., Schols L. and Riess O. 1998 Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease [letter]. Nat Genet, 18, 106-108.

Lambert P.D., Gross R., Nemeroff C.B. and Kilts C.D. 1995 Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann N Y Acad Sci, 757, 377-389.

Lillrank S.M., Lipska B.K. and Weinberger D.R. 1995 Neurodevelopmental animal models of schizophrenia. Clin Neurosci, 3, 98-104.

Lin B.Z., Pilch P.F. and Kandror K.V. 1997 Sortilin is a major protein component of Glut4-containing vesicles. J Biol Chem, 272, 24145-24147.

Lindstrom L.H., Widerlov E., Bisette G. and Neme-roff, C. 1988 Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophr Res, 1, 55-59.

Lipska B.K., Jaskiw G.E. and Weinberger D.R. 1993 Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology, 9, 67-75.

Manberg P.J., Nemeroff C.B., Bissette, G Widerlov, E., Youngblood W.W., Kizer J.S. and Prange A.J.Jr. 1985 Neuropeptides in CSF and post-mortem brain tissue of normal controls, schizophrenics and Huntington's choreics. Prog Neuropsychopharmacol Biol Psychiatry, 9, 97-108.

Maoret J.J., Anini Y., Rouyer-Fessard C., Gully D. and Laburthe M. 1999 Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xeno-grafted into nude mice. Int J Cancer, 80, 448-454.

Minagawa H., Shiosaka S., Inagaki S., Sakanaka M., Takatsuki K., Ishimoto I., Senba E., Kawai Y., Hara Y., Matsuzaki T. and Tohyama, M. 1983 Ontogeny of neurotensin-containing neuron system of the rat: immunohistochemical analysis--II. Lower brain stem. Neuroscience, 8, 467-486.

Moody T.W., Carney D.N., Korman L.Y., Gazdar A.F. and Minna J.D. 1985 Neurotensin is produced by and secreted from classic small cell lung cancer cells. Life Sci, 36, 1727-1732.

Moody T.W., Mayr C.A., Gillespie T.J. and Davis T.P. 1998 Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides, 19, 253-258.

Morris N.J., Ross S.A., Lane W.S., Moestrup, S.K., Petersen, C.M., Keller, S.R. and Lienhard, G.E. 1998 Sortilin is the major 110-kDa protein in GLUT4 vesi-cles from adipocytes. J Biol Chem, 273, 3582-3587.

Myers R.D. and Lee, T.F. 1983 In vivo release of dopamine during perfusion of neurotensin in substan-tia nigra of the unrestrained rat. Peptides, 4, 955-961.

Nemeroff C.B. 1980 Neurotensin: perchance an endo-genous neuroleptic? Biol Psychiatry, 15, 283-302.

Nemeroff C.B., Youngblood W.W., Manberg P.J., Prange A.J. and Kizer J.S. 1983 Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science, 221, 972-975.

O'Callaghan E., Sham P., Takei N., Glover G. and Murray R.M. 1991 Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet, 337, 1248-1250.

Okubo Y. Suhara T., Suzuki K. Kobayashi K. Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., Iyo, M., Tateno, Y. and Toru, M. 1997 Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 385, 634-636.

Papadimitriou A., Veletza V., Hadjigeorgiou, G.M., Patrikiou, A., Hirano, M. and Anastasopoulos, I. 1999 Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology, 52, 651-654.

Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Ruben-stein, J., Boyer, R., Stenroos, E.S., Chandrasekha-rappa S., Athanassiadou A., Papapetro-poulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio, G., Golbe, L.I. and Nussbaum, R.L. 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]. Science, 276, 2045-2047.

Poncelet M., Barnouin M.C., Breliere, J.C., Le Fur, G. and Soubrie, P. 1999 Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl), 144, 144-150.

Poustis C., Mazella J., Kitabgi P. and Vincent J.P. 1984 High-affinity neurotensin binding sites in differentiated neuroblastoma N1E115 cells. J Neurochem, 42, 1094-1100.

Ravikumar A., Arun P., Devi K.V. and Kurup P.A. 2000 Endogenous strychnine, nicotine, and morphine--description of hypo and hyper-strychninergic, nicoti-nergic and morphinergic state in relation to neuropsy-chiatric diseases. Indian J Exp Biol, 38, 559-566.

Read D. and Shulkes A. 1991 Ontogeny of neuro-tensin in the fetal sheep. J Dev Physiol, 16, 155-162.

Rivest R., St-Pierre S. and Jolicoeur F.B. 1991 Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat. Neuropharmacology, 30, 47-52.

Royston M.C., Slater P., Simpson M.D. and Deakin, J.F. 1991 Analysis of laminar distribution of kappa opiate receptor in human cortex: comparison between schizophrenia and normal. J Neurosci Methods, 36, 145-153.

Ruberg M. 2000 Maladie de Parkinson : vers un mécanisme de mort neuronale. Annales de l'Académie des Sciences, 25-45.

Sadoul J.L., Checler F., Kitabgi P., Rostene W., Javoy-Agid F. and Vincent J.P. 1984 Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. Biochem Biophys Res Commun, 125, 395-404.

Sams-Dodd F., Lipska B.K. and Weinberger,D.R. 1997 Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl), 132, 303-310.

Seethalakshmi L., Mitra S.P., Dobner P.R., Menon M. and Carraway R.E. 1997 Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate, 31, 183-192.

Sehgal I., Powers S., Huntley B., Powis G., Pittelkow, M. and Maihle N.J. 1994 Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A, 91, 4673-4677.

Sham P.C., O'Callaghan E., Takei N., Murray G.K., Hare E.H. and Murray, R.M. 1992 Schizophrenia following pre-natal exposure to influenza epidemics between 1939 and 1960. Br J Psychiatry, 160, 461-466.

Sharma R.P., Janicak P.G., Bissette G. and Nemeroff C.B. 1997 CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry, 154, 1019-1021.

Soyka M., Albus M., Kathmann N., Finelli A., Hofstetter S., Holzbach R., Immler B. and Sand P. 1993 Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci, 242, 362-372.

Swerdlow N.R. and Geyer M.A. 1998 Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull, 24, 285-301.

Tanji H., Araki T., Fujihara K., Nagasawa H. and Itoyama Y. 1999 Alteration of neurotensin receptors in MPTP-treated mice. Peptides, 20, 803-807.

Taylor M.D., De Ceballos M.L., Rose S., Jenner P. and Marsden, C.D. 1992 Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur J Pharmacol, 219, 183-192.

Tischler A.S., Lee Y.C., Slayton,V.W. and Bloom S.R. 1982 Content and release of neurotensin in PC12 pheochromocytoma cell cultures: modulation by dexamethasone and nerve growth factor. Regul Pept, 3, 415-421.

Tischler A.S., Lee Y.C., Slayton V.W. and Bloom S.R. 1983 Kinetics of regulation of neurotensin content in PC12 cells. Life Sci, 33, 347-351.

Torocsik A., Rakovska A., Gorcs T. and Vizi E.S. 1993 Effect of neurotensin and immunneutralization with antineurotensin-serum on dopaminergic-choli-nergic interaction in the striatum. Brain Res, 612, 306-312.

Uhl G.R., Whitehouse P.J., Price D.L., Tourtelotte W.W. and Kuhar M.J. 1984 Parkinson's disease: depletion of substantia nigra neurotensin receptors. Brain Res, 308, 186-190.

Vogel Z., Barg J., Levy R., Saya D., Heldman E. and Mechoulam R. 1993 Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem, 61, 352-355.

Wang F.L., Semchuk K.M. and Love E.J. 1994 Reliability of environmental and occupational exposure data provided by surrogate respondents in a case-control study of Parkinson's disease. J Clin Epidemiol, 47, 797-807.

Waters C.M., Hunt S.P., Jenner P. and Marsden C.D. 1987 Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res, 412, 244-253.

Watson C.G., Kucala T., Tilleskjor C. and Jacobs L. 1984 Schizophrenic birth seasonality in relation to the incidence of infectious diseases and temperature extremes. Arch Gen Psychiatry, 41, 85-90.

Weinberger D.R., Berman K.F. and Zec R.F. 1986 Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry, 43, 114-124.

Weinberger D.R., Berman K.F. and Illowsky B.P. 1988 Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry, 45, 609-615.

Widerlov E., Lindstrom L.H., Besev G., Manberg P.J., Nemeroff C.B., Breese G.R., Kizer J.S. and Prange A.J.Jr. 1982 Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry, 139, 1122-1126.

Wolf S.S., Hyde T.M., Saunders, R.C., Herman, M.M., Weinberger, D.R. and Kleinman, J.E. 1995 Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. J Neural Transm Gen Sect, 102, 55-65.

Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A. and et al. 1986 Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 234, 1558-1563.

Wood G.K., Lipska B.K. and Weinberger D.R. 1997 Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Brain Res Dev Brain Res, 101, 17-25.

Wood J.G., Hoang H.D., Bussjaeger L.J. and Solomon T.E. 1988a Effect of neurotensin on pancreatic and gastric secretion and growth in rats. Pancreas, 3, 332-339.

Wood J.G., Hoang H.D., Bussjaeger L.J. and Solomon T.E. 1988b Neurotensin stimulates growth of small intestine in rats. Am J Physiol, 255, G813-817.

Yamada M., Ohata H., Momose K. and Richelson E. 1995 Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Res Commun Mol Pathol Pharmacol, 90, 37-47.

Yamada M. and Richelson E. 1995 Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain. Neuroscience, 64, 405-417.

Yung A.R. and McGorry P.D. 1996 The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry, 30, 587-599.